Scarica l'app Stockscreener
1.0455
3.19%
-0.0345
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché PHIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.08
Aprire:
$1.08
Volume 24 ore:
124.48K
Relative Volume:
0.04
Capitalizzazione di mercato:
$11.25M
Reddito:
-
Utile/perdita netta:
$-11.66M
Rapporto P/E:
-0.1282
EPS:
-8.156
Flusso di cassa netto:
$-11.09M
1 W Prestazione:
-4.95%
1M Prestazione:
-17.02%
6M Prestazione:
-51.82%
1 anno Prestazione:
-45.83%
Intervallo 1D:
$1.04
$1.08
Intervallo di 1 settimana:
$1.00
$1.10
Portata 52W:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Nome
Phio Pharmaceuticals Corp
Settore
Industria
Telefono
(508) 767-3861
Indirizzo
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Confronta PHIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.045 | 11.63M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.43 | 117.45B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.10 | 82.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.79 | 52.92B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.00 | 52.02B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.24 | 37.94B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-05 | Iniziato | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
Phio Pharmaceuticals chairman Bitterman buys $5,100 in stock By Investing.com - Investing.com South Africa
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - TMX Newsfile
Phio To Commence A Toxicology Study For PH-762; Initiatives Underway For A Viable Product In 2026 - Nasdaq
Phio to begin FDA-required toxicology study for cancer drug PH-762 - Investing.com Nigeria
Phio Advances PH-762 With FDA-Backed Toxicology Study - TipRanks
Phio Pharmaceuticals Corp to begin toxicology study for PH-762 before human trialsSEC filing - marketscreener.com
Phio Pharmaceuticals (NASDAQ: PHIO) details FDA-cleared PH-762 tox study plan - Stock Titan
Phio Pharmaceuticals Corp Advances PH-762 Drug Development - TradingView — Track All Markets
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 - FinancialContent
Risk Off: Why Phio Pharmaceuticals Corp. stock appeals to dividend seekersJuly 2025 Decliners & Growth Focused Stock Pick Reports - Улправда
How Phio Pharmaceuticals Corp. stock benefits from strong dollarDip Buying & Detailed Earnings Play Alerts - Улправда
How Phio Pharmaceuticals Corp. stock responds to policy changesWeekly Trend Recap & Reliable Intraday Trade Alerts - Улправда
Can Phio Pharmaceuticals Corp. (44R1) stock sustain breakout momentum - DonanımHaber
How Phio Pharmaceuticals Corp. stock reacts to Fed rate cutsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - DonanımHaber
Why Phio Pharmaceuticals Corp. stock is a value investor pick2025 Technical Patterns & Free Weekly Chart Analysis and Trade Guides - Улправда
Why Phio Pharmaceuticals Corp. stock appeals to dividend seekersQuarterly Trade Review & Risk Managed Investment Strategies - Улправда
Why retail investors pile into Phio Pharmaceuticals Corp. stock2025 Earnings Impact & Daily Profit Focused Stock Screening - Улправда
How resilient is Phio Pharmaceuticals Corp. stock in market downturns2025 Market Sentiment & Weekly High Momentum Picks - Улправда
New Strong Buy Stocks for May 28th - MSN
MSN Money - MSN
We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run - MSN
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EBIT per share of Phio Pharmaceuticals Corp. – BER:44R1 - TradingView
Will Phio Pharmaceuticals Corp. (44R1) stock beat revenue estimatesMarket Performance Summary & Risk Managed Trade Strategies - Newser
How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesJuly 2025 Update & AI Optimized Trading Strategy Guides - Newser
How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulationsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser
What technical patterns form on Phio Pharmaceuticals Corp. (44R1) stock chartsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser
Will Phio Pharmaceuticals Corp. (44R1) stock rise with strong economyWeekly Trend Summary & Weekly High Return Stock Opportunities - Newser
Phio Pharma (PHIO) Stock Analysis Report | Financials & Insights - Benzinga
How Phio Pharmaceuticals Corp. (44R1) stock compares with market leadersPortfolio Update Summary & Reliable Entry Point Trade Alerts - Newser
What insider trading reveals about Phio Pharmaceuticals Corp. stockProfit Target & Verified Swing Trading Watchlists - Newser
Can Phio Pharmaceuticals Corp. stock continue upward trendMarket Sentiment Report & Real-Time Volume Analysis - Newser
Phio Pharmaceuticals Completes Enrollment for PH-762 Trial - MSN
TARC Limited Earnings Review What Investors Need to KnowMid Cap Growth Trends & Free Risk Assessment and Control - earlytimes.in
Phio Pharmaceuticals Completes Enrollment in Phase 1b Trial of PH-762 - TradingView — Track All Markets
Phio Pharmaceuticals Corp. Announces Completion of Enrollment in Phase 1B Clinical Trial of Intasyl Sirna Lead Compound Ph-762 - marketscreener.com
Phio completes enrollment in Phase 1b trial of skin cancer therapy - Investing.com Australia
Phio completes enrollment in Phase 1b trial of skin cancer therapy By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile
Phio Pharmaceuticals (NASDAQ: PHIO) Reports PH-762 Data With 6 Complete Responses - Stock Titan
[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan
It is Poised to be a Bull Market for Phio Pharmaceuticals Corp (PHIO) - Setenews
What is HC Wainwright’s Forecast for PHIO FY2025 Earnings? - Defense World
How higher bond yields impact Phio Pharmaceuticals Corp. (44R1) stockJuly 2025 Closing Moves & Smart Swing Trading Alerts - newser.com
Developing predictive dashboards with Phio Pharmaceuticals Corp. dataQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Phio Pharmaceuticals Corp files for offering of up to 11.8 million common shares by the Selling StockholdersSEC filing - MarketScreener
[S-3] Phio Pharmaceuticals Corp. Shelf Registration Statement | PHIO SEC FilingForm S-3 - Stock Titan
How Phio Pharmaceuticals Corp. (44R1) stock trades under stagflationMarket Activity Recap & AI Optimized Trade Strategies - newser.com
Published on: 2025-11-20 05:56:20 - newser.com
How Phio Pharmaceuticals Corp. stock performs in rate cut cyclesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Phio Pharmaceuticals Corp Azioni (PHIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phio Pharmaceuticals Corp Azioni (PHIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
0.20%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):